Today, a brief rundown of news involving Eisai, Biogen and Sanofi, as well as updates from Opthea, Novartis, and PTC Therapeutics.

Today, one of the more popular treatments for combatting Alzheimer's disease is Leqembi -- a drug developed by Biogen and Eisai. Of note, Eisai previously experienced a great deal of success with ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Ei­sai has slashed 2027 sales pro­jec­tions for its Bio­gen-part­nered Alzheimer’s treat­ment Leqem­bi by rough­ly half.

The new treatment is called LEQEMBI. If you or someone you know is facing Alzheimer's and would like to talk learn about LEQEMBI, click here.

Leqembi collected sales of 29.6 billion Japanese yen (about $194 million) over the last nine months of 2024, putting it on track to reach a 12-month sales target of 42.5 billion Japanese yen ($279 ...

According to Eisai's simulation, Leqembi sales will reach JPY 250 to 280 billion for their financial year (FY) 2027, which ends in March 2028. Eisai's presentation can be found on https://www ...

Sales of lecanemab (Leqembi), an FDA-approved Alzheimer’s drug, have climbed since 2023, despite questions about its effectiveness in women after Phase 3 trials showed limited benefit for females. A ...

Additionally, it is unclear the MoA would ensure that anti-inflammatory ... outperformed the difference versus placebo that Leqembi showed in Alzheimer’s disease, on the same rating scale ...

Leqembi is an infusion therapy approved by the Food and Drug Administration in 2023. It targets and removes the beta-amyloid plaque that builds up in the brain of Alzheimer's patients and causes ...